Literature DB >> 8389661

Preoperative therapy for intracaval and atrial extension of Wilms tumor.

M L Ritchey1, P P Kelalis, G M Haase, S J Shochat, D M Green, G D'Angio.   

Abstract

BACKGROUND: Primary surgical management of Wilms tumor with intravascular tumor extension is associated with significant morbidity. Retrospective analysis of a group of Wilms tumor patients with intravascular tumor extension treated with preoperative therapy was performed to evaluate the feasibility of this approach.
METHODS: Thirty children with caval (15 patients) or atrial (15 patients) extension of Wilms tumor who received preoperative therapy were reviewed. Patients were classified according to the stage of the disease as follows: (1) Stage III, 7 patients; (2) Stage IV, 18 patients; and (3) Stage V, 5 patients. The histologic type was favorable in 20 patients, anaplastic Wilms tumor in 7, and unknown in 3. All of the children received preoperative chemotherapy, ranging from 1-16 weeks with an average of 7.2 weeks.
RESULTS: One child died of progressive disease and another from toxicity before surgery. In 23 patients, a decrease in the size of the intravascular extension was noted preoperatively, without tumor embolization in any case. There was complete resolution of tumor thrombus in seven patients. Two-year survival for the entire group is 70%, with a median follow-up period of 21 months.
CONCLUSIONS: The use of preoperative therapy is appropriate in selected patients with extensive intravascular tumor involvement. Surgical management was facilitated in the majority of cases due to shrinkage of the primary tumor and reduction in the size of the tumor thrombus.

Entities:  

Mesh:

Year:  1993        PMID: 8389661     DOI: 10.1002/1097-0142(19930615)71:12<4104::aid-cncr2820711249>3.0.co;2-7

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Successful treatment of intracaval and atrial extension of Wilms' tumour by chemotherapy.

Authors:  S Berberoğlu; C Akyüz; M Büyükpamukçu
Journal:  Postgrad Med J       Date:  1996-12       Impact factor: 2.401

2.  Inferior vena cava involvement in children with Wilms tumor.

Authors:  Abeer Al Diab; Nader Hirmas; Abdellatif Almousa; Ramiz Abu-Hijlih; Fatinah Aljlouni; Iyad Sultan; Khalil Ghandour
Journal:  Pediatr Surg Int       Date:  2017-01-09       Impact factor: 1.827

3.  Intravascular extension of Wilms tumor.

Authors:  R C Shamberger; M L Ritchey; G M Haase; T L Bergemann; T Loechelt-Yoshioka; N E Breslow; D M Green
Journal:  Ann Surg       Date:  2001-07       Impact factor: 12.969

4.  Renal function after ifosfamide, carboplatin and etoposide (ICE) chemotherapy, nephrectomy and radiotherapy in children with Wilms tumour.

Authors:  Najat C Daw; David Gregornik; John Rodman; Neyssa Marina; Jianrong Wu; Larry E Kun; Jesse J Jenkins; Valerie McPherson; Judith Wilimas; Deborah P Jones
Journal:  Eur J Cancer       Date:  2008-11-06       Impact factor: 9.162

5.  Management and outcome of inoperable Wilms tumor. A report of National Wilms Tumor Study-3.

Authors:  M L Ritchey; K C Pringle; N E Breslow; J Takashima; J Moksness; C W Zuppan; J B Beckwith; P R Thomas; P P Kelalis
Journal:  Ann Surg       Date:  1994-11       Impact factor: 12.969

6.  Wilms tumor with intravascular tumor thrombus.

Authors:  Suna Emir
Journal:  Transl Pediatr       Date:  2014-01

7.  [Place of beating heart bypass surgery in kidney cancers with supradiaphragmatic invasion: about seven cases].

Authors:  Mounir Lahyani; Tarik Karmouni; Khalid Elkhader; Abdellatif Koutani; Ahmed Ibn Attya Andaloussi
Journal:  Pan Afr Med J       Date:  2014-12-16

8.  Impact of neoadjuvant chemotherapy on thrombus viability in patients with Wilms tumour and caval extension: systematic review with meta-analysis.

Authors:  T D Boam; M Gabriel; R Shukla; P D Losty
Journal:  BJS Open       Date:  2021-05-07

Review 9.  Adult Wilms tumor with inferior vena cava thrombus and distal deep vein thrombosis - a case report and literature review.

Authors:  Krzysztof Ratajczyk; Adrian Czekaj; Joanna Rogala; Pawel Kowal
Journal:  World J Surg Oncol       Date:  2018-02-23       Impact factor: 2.754

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.